Process Validation as a Lifecycle: Traditional, Hybrid and Continuous Verification

Process validation is no longer a one-off exercise of three batches. EU guidance treats it as a lifecycle, and the real test of control comes after approval.

Two documents, two audiences

Two EU texts work together. Annex 15 to the GMP Guide, in operation since 1 October 2015, sets out what the manufacturer must do on site. The EMA guideline on process validation for finished products explains what information and data must be provided in marketing authorisation applications. The latter frames process validation as a lifecycle activity, with ongoing process verification as its third stage.

The approaches Annex 15 recognises

  • Traditional (prospective) validation: a defined number of batches made under routine conditions. Annex 15 states that a minimum of three consecutive batches is generally acceptable, but the manufacturer should justify the number chosen.
  • Continuous process verification: an alternative where process knowledge and monitoring from development are strong enough to demonstrate control continuously.
  • Hybrid: a combination of the two, where some steps follow the traditional route and others the continuous one.
  • Concurrent validation: allowed only in exceptional, justified cases, for example where there is a strong benefit-risk case for patients.

Retrospective validation is not acceptable under Annex 15.

What the dossier must say

The EMA guideline expects the dossier to state which approach applies, and for a hybrid process which one applies to each step. Production-scale data may be required in certain situations, such as biological products or non-standard manufacturing methods. Where the process is standard, a validation scheme is submitted and the results are held at the site for inspection. Check the current guideline text for the exact conditions that apply to your product type.

Ongoing process verification

Annex 15 requires ongoing process verification under all approaches, conducted under an approved protocol or equivalent documents. It should show that the process remains in a state of control during commercial manufacture, using trended data on critical process parameters and quality attributes. Findings should be reported, reviewed and linked to the product quality review.

Practical points

  • Define critical quality attributes and critical process parameters before validation, not during it.
  • Qualify equipment and validate analytical methods first.
  • Use change control to decide whether a change requires revalidation, and keep the decision documented.
  • Align the validation approach in the dossier with what the site actually does.

A short self-check

  • Is the number of validation batches justified in writing for each product?
  • Is there an approved ongoing process verification protocol for every marketed product?
  • Do change control records state whether revalidation was considered?

How PQRA helps

PQRA supports marketing authorisation holders and manufacturers with validation master plans, protocols and reports, with the process validation sections of regulatory dossiers, and with ongoing process verification programmes. We help ensure what is written in the application matches what happens on the shop floor.

Contact PQRA to discuss how we can support your quality system.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *